Biotropics Malaysia Berhad

Imd Natural Solutions Gmbh

Prairie Berry Europe Gmbh

Imd Natural Solutions Gmb

Kathrin Reinhardt

Jens Bitzer

Bärbel Köpcke

Jana Moldenhauer

Marc Stadler

Torsten Grothe

Ingo Wöhrle

Joachim Hans

Thomas Küper

Matthias Gehling

Annie George

Ernst Roemer

Peter Reinemer

Nur Hanisah Mohtar

Noorsyarida Mohd Sapiai

Barbel Kopcke

Ingo WÖHRLE

The invention relates to the use of, and methods of use employing, certain glycolipid compounds as defined in detail below and having preservative or antimicrobial properties, novel compounds of the glycolipid class, and related invention embodiments. The compounds have the formula I wherein m is 3 to 5, n is 2 to 5, o is 0 or 1 and p is 3 to 17, with the proviso that the sum m+n+o+p is not less than 14; andR is a carbohydrate moiety bound via one of its carbon atoms to the binding oxygen,and/or a physiologically, especially pharmaceutically or nutraceutically or cosmetically, acceptable salt thereof, or an ester thereof,as such or in the form of a composition,where the compound may be present in open chain form and/or in the form of a lactone (FIG.).

Long chain glycolipids useful to avoid perishing or microbial contamination of materials

The present invention relates to certain polyhydroxylated pentacyclic triterpene acids of formula (I) for use as HMG-CoA reductase inhibitors in the prophylactic and/or therapeutic treatment of a disease, disorder or condition that responds to a reduction of the HMG-CoA reductase activity in a mammal, preferably a human being. The present invention further relates to certain mixtures and plant extracts comprising euscaphic acid and tormentic acid, wherein the amount of euscaphic acid to tormentic acid exceeds a certain ratio. Further, the present invention also relates to a formulation, preferably pharmaceutical or nutraceutical formulation, comprising one or more of said compounds of formula (I), a composition according to the present invention or a plant extract according to the present invention. Also, the present invention relates to a process for obtaining certain polyhydroxylated pentacyclic triterpene acids of formula (I), a composition according to the present invention or a plant extract according to the present invention.

Polyhydroxylated pentacyclic triterpene acids as HMG-COA reductase inhibitors

The use or methods of use of extracts comprising one or more special clerodane compounds against inflammatory (including allergic) diseases or conditions, as well as novel compounds of this type, said clerodane derivatives for use against inflammatory (including allergic) diseases or conditions, pharmaceutical formulations comprising them especially for use against inflammatory disease or conditions, and related embodiments; said extract and/or compound(s) for use in the treatment or in the preparation of a medicament (including a nutraceutical) for the prophylactic and/or therapeutic treatment of said disease or condition, as well as their preparation; pharmaceutical or nutraceutical formulations comprising said extract and/or natural compound(s) which are useful in said prophylactic and/or therapeutic treatment, and related embodiments.

Clerodane derivatives for modulation of leukotriene receptor activity and related diseases

Growing community of inventors

Dortmund, Germany

Kathrin Reinhardt